Summary: Human cytochrome P450 (CYP) is a superfamily of hemoproteins which oxidize a number of endogenous compounds and xenobiotics. The human CYP2C subfamily consists of four members: CYP2C8, CYP2C9, CYP2C18 and CYP2C19. CYP2C9 and CYP2C19 are important drug-metabolizing enzymes and together metabolize approximately 20% of therapeutically used drugs. Forty-two allelic variants for CYP2C9 and 34 for CYP2C19 have been reported. The frequencies of these variants show marked inter-ethnic variation. The functional consequences of genetic polymorphisms have been examined, and many studies have shown the clinical importance of these polymorphisms. Current evidence suggests that taking the genetically determined metabolic capacity of CYP2C9 and CYP2C19 into account has the potential to improve individual risk/benefit relationships. However, more prospective studies with clinical endpoints are needed before the paradigm of "personalized medicine" based on the variants can be established. This review summarizes the currently available important information on this topic.
Introduction
The cytochrome P450 (CYP) superfamily comprises important phase I drug-metabolizing enzymes that oxidize more than 90% of current therapeutic drugs. Over 90% of human drug oxidation can be attributed to CYP1A2, 2A6, 2C9, 2C19, 2E1, 2D6 and 3A4. 1) Genetically determined differences in drug-metabolizing enzymatic activity can lead to broad inter-individual variability in drug responses, resulting in altered efficacy or toxicity in individuals. 2) Genetic variants in the CYP2C subfamily have been most widely studied. The human CYP2C subfamily consists of four members (CYP2C8, CYP2C9, CYP2C18 and CYP2C19). Their genes are tandemly located at 10q24.
3) Genetic variants in CYP2C9 and CYP2C19 have been shown to have clinical consequences resulting in the toxicity and altered efficacy of many drugs.
CYP2C9 is one of the most important CYPs 4) and is involved in approximately 20% of P450-mediated drug oxidation reactions. [4] [5] [6] The frequency of non-functional alleles in the CYP2C9 gene is relatively low. 7, 8) However, these variants are important because CYP2C9 metabolizes many clinically important drugs. Of special interest is the CYP2C9-mediated metabolism of drugs with a narrow therapeutic index, such as warfarin and phenytoin, because a marked impairment in CYP2C9 metabolic activity can lead to severe toxicity. 9, 10) CYP2C19 is a polymorphically expressed cytochrome P450 responsible for the metabolism of several clinically used drugs, including some barbiturates, diazepam, proguanil, propranolol and several proton pump inhibitors. Clinical studies evaluating the contribution of all known CYP2C9 and CYP2C19 non-functional alleles to pharmacokinetics have been described. The purpose of this report is to review the clinical impact of variants of the CYP2C9 and 2C19 genes.
CYP2C9
General feature: CYP2C9 consists of nine exons encoding a protein of 490 amino acids. 11) CYP2C9 is one of the most abundant CYP enzymes in the adult human liver (³20% of hepatic total CYP content).
11) It metabolizes a number of important clinical drugs including antibiotic, anticancer, antidiabetic, antiepileptic, antihypertensive, cannabinol, non-steroidal anti-inflammatory, anticoagulant, and anti-hyperlipidemic drugs ( Table 1) . To date, 42 alleles have been identified in the human CYP2C9 gene (*1A through to *35) (http://www.cypalleles.ki.se/cyp2c9.htm, access date: 19 July 2012). CYP2C9*1A is referred to as the wild type. The most common variant is CYP2C9*2, consisting of three alleles (CYP2C9*2A, *2B and *2C), a missense mutation of 430C>T in exon 3 causing a non-synonymous substitution (R144C). The R144C substitution in CYP2C9*2 has been suggested to affect the interaction between the P450 enzyme and P450 reductase, 12) which might explain the slower metabolism of some CYP2C9 substrates. CYP2C9*3, with an I359L mutation, is one of the most widely studied variants. Residue 359 is located at CYP2C9's active site, where it participates in substrate recognition. 13) In vitro studies show it significantly impairs catalytic activity toward various CYP2C9 substrates relative to the wild type.
14) CYP2C9*4 is a rare missense mutation of 1076T>C (I359T) originally identified in a Japanese epilepsy patient with an adverse reaction to phenytoin. 15) CYP2C9*5 contains the 1080C>G transversion in exon 7 that leads to D360E, which has been found almost exclusively in African Americans. [16] [17] [18] CYP2C9*6 has a deletion of A818 in exon 5 originally identified in an African American patient with high sensitivity to phenytoin. 17, 19) CYP2C9*7, *8, *9, *10, *11 and *12 produced the following coding changes: L19I, R150H, H251R, E272G, R335W and R489S, respectively. CYP2C9*11 and CYP2C9*12 significantly decreased the tolbutamide hydroxylation in vitro, while CYP2C9*8 significantly increased metabolic activity. 20) CYP2C9*7, CYP2C9*9 and CYP2C9*10 showed no effect on the metabolisms of tolbutamide.
21) CYP2C9*13 has been identified in a Chinese poor metabolizer of lornoxicam and the allele has a T269C transversion in exon 2 causing an L90P substitution. 22) For most identified variants except for CYP2C9*2 and CYP2C9*3, their functional significance in vivo is currently unknown due to extremely low frequencies.
Impact of variants on clinical pharmacokinetics: CYP2C9*2 and CYP2C9*3 are well researched in clinical pharmacokinetic studies ( Table 2 ). Both variants show significantly reduced CL/F values for ibuprofen and warfarin. [23] [24] [25] [26] [27] [28] Yuen et al. reported that the presence of the CYP2C9*2 or CYP2C9*3 allele reduced mean S-warfarin clearance by 35%. 25) It was reported that impaired metabolism of ibuprofen is associated with the presence not only of CYP2C9*3, but also of CYP2C9*2 and CYP2C8*3.
23)
CYP2C9*2 and CYP2C8*3 are often associated 24, 29, 30) ; thus it is of particular importance to analyze their combined effect.
On the other hand, the pharmacokinetic parameters of "9-tetrahydrocannabinol, fluvastatin, glyburide, glimepiride, torse- mide, celecoxib and tenoxicam were not affected by the CYP2C9*2 allele, but CYP2C9*3 carriers had significantly high AUC or low CL/F values in comparison with carriers of the wild type. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Kirchheiner et al. reported a more than two-fold decrease in CL/F for celecoxib among homozygous carriers of CYP2C9*3 compared to carriers of the wild type genotype CYP2C9*1/*1 and heterozygous carriers of one CYP2C9*3 allele, whereas CYP2C9*2 had no significant influence on celecoxib's pharmacokinetics. 36) A clinical study showed significant increases for CYP2C9*3 vs. CYP2C9*1 and CYP2C9*2 in the AUC 0¼ä nd T 1/2 of tenoxicam. 40) The functional effect of CYP2C9*2 appears to be mediated by a change in the interaction with the cytochrome-P450 reductase, 12) and CYP2C9*3 has been suggested to affect substrate recognition. 13) In addition, in vitro data showed that CYP2C9*2 resulted in a moderate reduction in V max in most cases. 41) These may be explanations for the different impact on pharmacokinetics between CYP2C9*2 and CYP2C9*3.
The CYP2C9*8 variant is derived from a 3627G>A transversion in exon 3 that results in an R150H substitution, and has no effect on the metabolism of losartan in vivo.
16) However, recently Liu et al. reported that warfarin-treated patients with the CYP2C9*8 allele (heterozygotes or homozygotes) had 68.7% lower clearance of S-warfarin than did CYP2C9*1 homozygotes. 42) The magnitude of the reduction in enzymatic activity with different CYP2C9 variants has been reported to be highly substratedependent. 43) Kumar et al. suggests that substrates bind to different regions or in different orientations within the large active site of CYP2C9, 44) and this may potentially provide an explanation for the substrate-dependent effects of CYP2C9 variants on enzymatic activity.
CYP2C19
General features: CYP2C19 plays a critical role in the oxidative biotransformation of several important groups of drugs, including anticancer, antidepressant, antihypertensive, antiplatelet and antiulcer drugs ( Table 1) . The CYP2C19 gene is located on chromosome 10 (10q24.1-q24.3), and has nine exons encoding a protein of 490 amino acids. To date, 34 alleles of the human CYP2C19 gene have been identified and characterized (http:// www.cypalleles.ki.se/cyp2c19.htm, access date: 19 July 2012). CYP2C19*2 and CYP2C19*3 account for the majority of the defective genotypes. CYP2C19*2 carries a 681A>G change in exon 5, which leads to a splicing defect. 45 ) CYP2C19*3 has a 636G>A change in exon 4 that produces a premature stop codon. 46) CYP2C19*2 and CYP2C19*3 generate null-activity enzymes and have been considered to account for >99% of poor metabolizer (PM) alleles in Japanese populations. PM alleles are found in 3-5% of Caucasians, and 12-23% of Asians.
11) Moreover, CYP2C19*17, characterized by a ¹806C>T change in the 5A-flanking region of the gene, which was identified by Sim et al., 47) is associated with increased CYP2C19 expression and enzymatic activity. Thus, CYP2C19*17 is considered an ultra-rapid metabolizer (UM) allele. The CYP2C19*17 allele is found in 18-27% of Europeans, 0.15-0.44% of Asians and 10-26% of Africans. The alleles initially known as CYP2C19*20 and CYP2C19*21 were demonstrated to be CYP2C19*3B and CYP2C19*2C, respectively. CYP2C19*4, *5, *6, *7 and *8 have been reported to cause a loss of enzymatic activity and there are few reports about other alleles' functions.
Impact of variants on clinical pharmacokinetics: The alleles CYP2C19*2, CYP2C19*3 and CYP2C19*17 are well HV, healthy volunteer.
CYP2C9 and CYP2C19 Gene Polymorphismsstudied. 48) For lansoprazole and pantoprazole, which are also metabolized by CYP2C19, there were again significant differences in these parameters between EMs and PMs. Among patients infected with Helicobacter pylori, serum concentrations of lansoprazole were lower in EMs than PMs (p < 0.001). 49) However, for rabeprazole, another PPI, there was no difference in plasma concentrations. 50) Some other enzyme (e.g., CYP3A4) or nonenzymatic reaction may contribute to the metabolism of rabeprazole rather than CYP2C19. Clopidogrel is an oral antiplatelet agent used to prevent blood clots in cardiac disorders. It is a prodrug, which is converted to its active form by CYP2C19. The CYP2C19*2 and CYP2C19*3 alleles are associated with reduced levels of clopidogrel's active metabolite. In healthy volunteers, the AUC and C max of this active metabolite are significantly decreased (p < 0.05). 51) These alleles of CYP2C19 are determinants for the formation of the active metabolite and its antiplatelet effects. Similarly, voriconazole (an antifungal) and phenytoin (an anticonvulsant) are metabolized by CYP2C19 and there are also significant differences in pharmacokinetic parameters between EMs and PMs.
It was reported that the CYP2C19*17 allele is associated with a decrease in pantoprazole serum concentrations.
52) The same effect of CYP2C19*17 has been identified for many drugs, including escitalopram, clopidogrel and voriconazole. These results suggest that carriers of the CYP2C19*17 allele should be classified as UMs. However, Li-Wan-Po et al. reported that assigning CYP2C19*17 homozygotes as EMs rather than UMs is adequate, because the range of the omeprazole metabolic ratio overlapped for all genotypes including CYP2C19*1 and *17.
53) Furthermore, for escitalopram and sertraline, CYP2C19*17 caused no remarkable difference in the pharmacokinetic parameters compared to the wild type. 53) Thus, CYP2C19*17 has no major impact on enzymatic activity like that of CYP2C19*2 or CYP2C19*3. But it is clear that CYP2C19*17 influences the pharmacokinetics of certain drugs (Table 3) . Indeed, CYP2C19*17 genotyping is essential for clopidogrel treatment in Caucasian and African populations due to relatively higher frequency compared to Asian populations. 54) Although it is still controversial whether CYP2C19*17 is a UM or EM allele, collective evidence supports the hypothesis that the CYP2C19*17 allele activates its metabolic function. There is insufficient data to evaluate the contribution of CYP2C19 genetic variants to the pharmacokinetics of clinically used drugs. Functional variants continue to be studied with respect to their effect on the toxicity and efficacy of the drugs.
Conclusion
CYP2C9 and CYP2C19 are highly polymorphic. A number of clinical studies have addressed the impact of CYP2C9 and CYP2C19 polymorphisms on the clearance and/or therapeutic response of drugs that are substrates of CYP2Cs. For many substrate drugs, a clear gene-dose and gene-effect relationship has been observed in healthy volunteers and patients. In this regard, CYP2C9 and CYP2C19 variants can be considered a useful HV, healthy volunteer.
CYP2C9 and CYP2C19 Gene Polymorphismsbiomarker in monitoring drug responses and adverse effects. In order for pharmacogenetic information to be useful clinically, there must be enough evidence of the impact of genetic variation in the CYP2C subfamily on clinical pharmacokinetics. In addition to the genetic polymorphisms, various mechanisms offer another potential explanation for the inter-individual differences in CYP2C9 and CYP2C19 expression. It is well known that alternative splicing generates variants resulting in a loss of the function. Indeed, Ariyoshi et al. reported that a CYP2C9 splicing variant is expressed in most human livers in Caucasians. 55) Recently, it was reported that CYP2C8 is regulated post-transcriptionally by microRNAs (miRNAs: miR-103 and 107) in the human liver. 56) Interestingly, potential recognition sites for miRNA motifs were also found in the 3A-untranslated region of CYP2C9 and CYP2C19, suggesting the same miRNAs could regulate the translation of other members of the CYP2C subfamily. Compared to the established contribution of genetic polymorphisms in CYP2C9 and CYP2C19 genes to the inter-individual variability in pharmacokinetic parameters, the role of miRNA for regulating CYP2C gene expression has not yet been clarified. Additional studies of not only genetic variants but also various mechanisms regulating gene expression are important for establishing the clinical usefulness of genotyping CYP2Cs.
